Safety and efficacy of two preparations of megestrol acetate in HIV-infected individuals with weight loss in Africa, India, and the United States

Journal of Applied Research

Volumn 7, Issue 3, 2007, Pages 206-216

  Wanke, Christine ^a   Gutierrez, Jodi ^b   Kristensen, Allan ^b   MacEarchern, Laureen ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Par Pharmaceutical   (United States)

Author keywords

Africa; Cortisol; HIV infection; India; Intervention; Megestrol acetate; Weight loss

Indexed keywords

CORTICOTROPIN; EFAVIRENZ; HEMOGLOBIN A1C; HYDROCORTISONE; LIPID; MEGESTROL ACETATE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADRENAL GLAND; ADULT; AFRICA; ANALYTIC METHOD; APPETITE; ARM CIRCUMFERENCE; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULARY; DRUG SAFETY; ENDOCRINE FUNCTION; FEMALE; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCORTISONE BLOOD LEVEL; IMPEDANCE; INDIA; LEAN BODY WEIGHT; LIPID ANALYSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLISM; OPEN STUDY; PATIENT COMPLIANCE; PATIENT MONITORING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TRICEPS BRACHII MUSCLE; UNITED STATES; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; WAIST CIRCUMFERENCE; WASTING SYNDROME; WEIGHT GAIN;

EID: 36148989858     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Wanke CA, Silva M, Knox TA, Forrester J, et al. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;31:803-805.
2. Pujol RM, Domingo P, Xavier MG, et al. HIV-1 protease inhibitor-associated partial lipodystrophy: clinicopathologic review of 14 cases. J Am Acad Dermatol. 2000;42:193-198.
3. Kamradt T, Niese D, Vogel F. Slim disease (AIDS). Lancet. 1985;2:1425.
4. Mhiri C, Belec L, Di Costanzo B, et al. The slim disease in African patients with AIDS. Trans R Soc Trop Med Hyg. 1992;86:303-306.
5. Lucas SB, De Cock KM, Hounnou A, et al. Contribution of tuberculosis to slim disease in Africa. BMJ. 1994;308:1531-1533.
6. Serwadda D, Mugerwa RD, Sewankambo NK, et al. Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet. 1985;2:849-852.
7. Wheeler DA. Weight loss and disease progression in HIV infection. AIDS Read. 1999;9:347-353.
8. Tang AM, Forrester J, Spiegelman D, et al. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:230-236.
9. Wilson IB, Roubenoff R, Knox TA, et al. Relation of lean body mass to health-related quality of life in persons with HIV. J Acquir Immune Defic Syndr. 2000;24:137-146.
10. Wilson IB, Jacobson DL, Roubenoff R, et al, Gorbach SL. Changes in lean body mass and total body weight are weakly associated with physical functioning in patients with HIV infection. HIV Med. 2002;3:263-270.
11. Mangili A, Murman DH, Zampini AM, Wanke CA. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clin Infect Dis. 2006;42:836-842.
12. Kotler D, Wanke C. Management of HIV wasting syndrome: a consensus conference. J Acquir Immune Defic Syndr. 2004;37:S261.
13. Von Roenn JH. Randomized trials of megestrol acetate for AIDS-associated anorexia and cachexia. Oncology. 1994;51 Suppl 1:19-24.
14. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med. 1994;121:393-399.
15. Oster MH, Enders SR, Samuels SJ, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med. 1994;121:400-408.
16. Mwamburi DM, Gerrior J, Wilson IB, et al. Combination megestrol acetate, oxandrolone, and dietary advice restores weight in human immunodeficiency virus. Nutr Clin Pract. 2004;19:395-402.
17. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol. 1993;11:152-154.
18. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2005;CD004310.
19. Bell SJ, Hestnes JC, Wanke C, Forse RA. Megestrol acetate in patients with AIDS-related cachexia. JPEN J Parenter Enteral Nutr. 1996;20:165-166.
20. Mwamburi DM, Gerrior J, Wilson IB, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months. Clin Infect Dis. 2004;38:895-902.
21. Chidakel AR, Zweig SB, Schlosser JR, Homel P, Schappert JW, Fleckman AM. High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate. J Endocrinol Invest 2006;29:136-140.
22. Naing KK, Dewar JA, Leese GP. Megestrol acetate therapy and secondary adrenal suppression. Cancer. 1999;86:1044-1049.
23. Wermers RA, Hurley DL, Kearns AE. Osteoporosis associated with megestrol acetate. Mayo Clin Proc. 2004;79:1557-1561.
24. Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med. 1995;122:843-845.
25. Cella DF, VonRoenn J, Lloyd S, Browder HP. The Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI): a brief assessment of patients' subjective response to treatment for anorexia/cachexia. Quality of Life Research. 1995;4:221-231.
26. Mwamburi DM, Wilson IB, Jacobson DL, et al. Understanding the role of HIV viral load in determining weight change in the era of HAART. Clin Infect Diseases. Clinical Infectious Diseases 2005; 40(1):167-173.